CROI 2015: Study Finds High Rates of Cancer Among Elderly People with HIV

Elderly people living with HIV (over the age of 65) are at greatly increased risk of HIV-associated cancers, though many of the most commonly diagnosed cancers may be related more to aging than to HIV itself, according to a study reported last week at the at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).


CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP

Levels of the HIV entry inhibitor maraviroc (Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection against HIV in a laboratory study, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Multiple doses, however, could still potentially be effective for pre-exposure prophylaxis, or PrEP.


CROI 2015: Similar Fat Gain Seen with Different Antiretroviral Regimens [VIDEO]

People starting antiretroviral therapy containing raltegravir (Isentress) and those starting boosted atazanavir (Reyataz) or darunavir (Prezista) experienced significant increases in both abdominal and limb fat, with no evidence of greater fat gains among those taking HIV protease inhibitors, according to findings presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.


[Grace McComsey, CROI, February 26, 2015]

"We saw a significant increase in peripheral and central fat with all the regimens," McComsey said, describing results from the ACTG 5260s substudy at a CROI press conference. "We used to think protease inhibitors were associated with central fat accumulation, but here even an integrase inhibitor made patients gain as much fat."

She added, however, that people who started antiretroviral therapy before they experienced advanced immune suppression gained less fat, suggesting that this is another reason to start people on treatment "right away, regardless of CD4 count."



GA McComsey, C Moser, JS Currier, et al. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors
. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 140.

CROI 2015: Disappointing Result for Tenofovir Gel Microbicide

Among some highly promising results from HIV prevention studies presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle, there was one disappointment. FACTS 001, a study testing the efficacy against HIV of a vaginal microbicide gel containing tenofovir, produced a null result: there was no difference in the HIV infection rate for young women given the active gel and the rate for those given a placebo gel.


Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care. coverage by topic

CROI website



CROI 2015: Tenofovir Vaginal Gel Not Effective Overall Against HIV [VIDEO]

The FACTS 001 trial evaluating a vaginal microbicide gel containing tenofovir did not show overall effectiveness for preventing HIV infection among young women in South Africa, although the product did appear to provide some protection for women who were able to use it consistently, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.


CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.